These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 12460696)

  • 1. Left ventricular mass change during treatment and outcome in patients with essential hypertension.
    Koren MJ; Ulin RJ; Koren AT; Laragh JH; Devereux RB
    Am J Hypertens; 2002 Dec; 15(12):1021-8. PubMed ID: 12460696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of left ventricular mass change during treatment of hypertension.
    Devereux RB; Wachtell K; Gerdts E; Boman K; Nieminen MS; Papademetriou V; Rokkedal J; Harris K; Aurup P; Dahlöf B
    JAMA; 2004 Nov; 292(19):2350-6. PubMed ID: 15547162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Wachtell K; Dahlöf B; Rokkedal J; Papademetriou V; Nieminen MS; Smith G; Gerdts E; Boman K; Bella JN; Devereux RB
    Am Heart J; 2002 Dec; 144(6):1057-64. PubMed ID: 12486431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study.
    Wachtell K; Gerdts E; Aurigemma GP; Boman K; Dahlöf B; Nieminen MS; Olsen MH; Okin PM; Palmieri V; Rokkedal JE; Devereux RB
    Blood Press; 2010 Jun; 19(3):169-75. PubMed ID: 20438307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Left Ventricular Hypertrophy in Hypertensive Athletes can be Reduced by Antihypertensive Medication Despite Continuing Intense Aerobic Exercise.
    Ketelhut S; Franz IW; Ketelhut RG
    High Blood Press Cardiovasc Prev; 2018 Dec; 25(4):385-390. PubMed ID: 30341642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of serial changes in left ventricular mass in essential hypertension.
    Verdecchia P; Schillaci G; Borgioni C; Ciucci A; Gattobigio R; Zampi I; Reboldi G; Porcellati C
    Circulation; 1998 Jan 6-13; 97(1):48-54. PubMed ID: 9443431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of overweight and obesity on cardiac benefit of antihypertensive treatment.
    Gerdts E; de Simone G; Lund BP; Okin PM; Wachtell K; Boman K; Nieminen MS; Dahlöf B; Devereux RB
    Nutr Metab Cardiovasc Dis; 2013 Feb; 23(2):122-9. PubMed ID: 21775111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Left ventricular concentric geometry during treatment adversely affects cardiovascular prognosis in hypertensive patients.
    Muiesan ML; Salvetti M; Monteduro C; Bonzi B; Paini A; Viola S; Poisa P; Rizzoni D; Castellano M; Agabiti-Rosei E
    Hypertension; 2004 Apr; 43(4):731-8. PubMed ID: 15007041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy.
    Solomon SD; Appelbaum E; Manning WJ; Verma A; Berglund T; Lukashevich V; Cherif Papst C; Smith BA; Dahlöf B;
    Circulation; 2009 Feb; 119(4):530-7. PubMed ID: 19153265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regression of echocardiographic left ventricular hypertrophy after 2 years of therapy reduces cardiovascular risk in patients with essential hypertension.
    Pierdomenico SD; Lapenna D; Cuccurullo F
    Am J Hypertens; 2008 Apr; 21(4):464-70. PubMed ID: 18369364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in left ventricular geometry during antihypertensive treatment.
    Salvetti M; Paini A; Bertacchini F; Stassaldi D; Aggiusti C; Agabiti Rosei C; Bassetti D; Agabiti-Rosei E; Muiesan ML
    Pharmacol Res; 2018 Aug; 134():193-199. PubMed ID: 29959031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of antihypertensive therapy on blood pressure and left ventricular hypertrophy in patients with severe hypertension.
    Sumino H; Nakamura T; Kanda T; Sakamaki T; Sato K; Saito Y; Hoshino J; Kurashina T; Ono Z; Takahashi T; Ichikawa S; Kurabayashi M; Nagai R
    Jpn Heart J; 2000 May; 41(3):339-48. PubMed ID: 10987352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of left ventricular diastolic dysfunction in patients with left ventricular hypertrophy and systemic hypertension (the LIFE Study).
    Wachtell K; Palmieri V; Gerdts E; Bella JN; Aurigemma GP; Papademetriou V; Dahlöf B; Aalto T; Ibsen H; Rokkedal JE; Devereux RB
    Am J Cardiol; 2010 Oct; 106(7):999-1005. PubMed ID: 20854964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Left ventricular mass regression in the LIFE study: effect of previous antihypertensive treatment.
    Aurigemma GP; Devereux RB; Wachtell K; Palmieri V; Boman K; Gerdts E; Nieminen MS; Papademetriou V; Dahlöf B
    Am J Hypertens; 2003 Mar; 16(3):180-6. PubMed ID: 12620695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exercise and cardiovascular outcomes in hypertensive patients in relation to structure and function of left ventricular hypertrophy: the LIFE study.
    Boman K; Gerdts E; Wachtell K; Dahlöf B; Nieminen MS; Olofsson M; Papademetriou V; Devereux RB
    Eur J Cardiovasc Prev Rehabil; 2009 Apr; 16(2):242-8. PubMed ID: 19369828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of four antihypertensive monotherapies on cardiac mass and function in hypertensive patients with left ventricular hypertrophy: randomized prospective study.
    Rakić D; Rumboldt Z; Bagatin J; Polić S
    Croat Med J; 2002 Dec; 43(6):672-9. PubMed ID: 12476475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Left ventricular midwall function improves with antihypertensive therapy and regression of left ventricular hypertrophy in patients with asymptomatic hypertension.
    Schussheim AE; Diamond JA; Phillips RA
    Am J Cardiol; 2001 Jan; 87(1):61-5. PubMed ID: 11137835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.
    Devereux RB; Dahlöf B; Gerdts E; Boman K; Nieminen MS; Papademetriou V; Rokkedal J; Harris KE; Edelman JM; Wachtell K
    Circulation; 2004 Sep; 110(11):1456-62. PubMed ID: 15326072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of angiotensin II receptor blockade-based therapy with losartan on left ventricular hypertrophy and geometry in previously treated hypertensive patients.
    Cuspidi C; Meani S; Valerio C; Fusi V; Sala C; Maisaidi M; Zanchetti A
    Blood Press; 2006; 15(2):107-15. PubMed ID: 16754274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of enalapril versus nifedipine to decrease left ventricular hypertrophy in systemic hypertension (the PRESERVE trial).
    Devereux RB; Dahlof B; Levy D; Pfeffer MA
    Am J Cardiol; 1996 Jul; 78(1):61-5. PubMed ID: 8712120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.